- Home
- SPPL vs BFRI Comparison
SPPL vs BFRI Comparison
Compare SPPL & BFRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPPL
- BFRI
- Stock Information
- Founded
- SPPL 2016
- BFRI 1997
- Country
- SPPL Singapore
- BFRI United States
- Employees
- SPPL N/A
- BFRI N/A
- Industry
- SPPL
- BFRI Biotechnology: Pharmaceutical Preparations
- Sector
- SPPL
- BFRI Health Care
- Exchange
- SPPL Nasdaq
- BFRI Nasdaq
- Market Cap
- SPPL 5.8M
- BFRI 6.2M
- IPO Year
- SPPL 2023
- BFRI 2021
- Fundamental
- Price
- SPPL $1.20
- BFRI $0.87
- Analyst Decision
- SPPL
- BFRI Strong Buy
- Analyst Count
- SPPL 0
- BFRI 1
- Target Price
- SPPL N/A
- BFRI $7.00
- AVG Volume (30 Days)
- SPPL 34.4M
- BFRI 7.3M
- Earning Date
- SPPL 11-29-2024
- BFRI 11-13-2024
- Dividend Yield
- SPPL N/A
- BFRI N/A
- EPS Growth
- SPPL N/A
- BFRI N/A
- EPS
- SPPL N/A
- BFRI N/A
- Revenue
- SPPL $3,550,862.00
- BFRI $35,358,000.00
- Revenue This Year
- SPPL N/A
- BFRI $19.11
- Revenue Next Year
- SPPL N/A
- BFRI $20.16
- P/E Ratio
- SPPL N/A
- BFRI N/A
- Revenue Growth
- SPPL N/A
- BFRI 5.17
- 52 Week Low
- SPPL $0.25
- BFRI $0.61
- 52 Week High
- SPPL $9.69
- BFRI $4.04
- Technical
- Relative Strength Index (RSI)
- SPPL 58.84
- BFRI 49.94
- Support Level
- SPPL $1.11
- BFRI $0.65
- Resistance Level
- SPPL $1.56
- BFRI $0.79
- Average True Range (ATR)
- SPPL 0.32
- BFRI 0.11
- MACD
- SPPL 0.01
- BFRI -0.00
- Stochastic Oscillator
- SPPL 40.54
- BFRI 53.55
About SPPL SIMPPLE LTD.
Simpple Ltd delivers an ecosystem solution that combines Internet-of-Things devices, robotic solutions and an integrated software system operating in unison to position buildings to be future-ready. The company operates through two primary segments: the sale, warranty, and maintenance of autonomous robotic cleaning equipment (Robots), and the sale of facilities management software. The majority of its revenue is generated from the Robots segment.
About BFRI Biofrontera Inc.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. Its licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its licensed product is Ameluz, which is a prescription drug approved for use in combination with the RhodoLED lamp series, for PDT (when used together, Ameluz PDT). including the complementary product BF-RhodoLED, and Xepi.